Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 12;20(1):104.
doi: 10.1186/s12884-020-2789-2.

First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases

Affiliations

First-trimester maternal serum alpha-fetoprotein is not a good predictor for adverse pregnancy outcomes: a retrospective study of 3325 cases

Jilin Hu et al. BMC Pregnancy Childbirth. .

Abstract

Background: It is well known that second-trimester maternal serum alpha-fetoprotein (MS-AFP) is a predictor for adverse pregnancy outcomes (APOs), such as preterm birth, stillbirth, preeclampsia and small for gestational age (SGA). However, it is unknown whether first-trimester MS-AFP is also predictive of APOs.

Methods: We retrospectively reviewed the data on the first-trimester MS-AFP levels and pregnancy outcomes of 3325 singleton pregnant women. The cutoff value of 2.5 multiple of the median (MoM) was used to evaluate the risks of APOs regarding MS-AFP. The receiver operating characteristic (ROC) curves were used to evaluate the predictive efficiencies of MS-AFP to these disorders.

Results: A total of 181 pregnancies resulted in preterm birth, 32 in stillbirth, 81 in preeclampsia, and 362 in SGA. Compared to women with MS-AFP < 2.5MoM, those with MS-AFP ≥ 2.5MoM had increased risks (odds ratio, 95% confidence interval) of preterm birth (2.53, 1.65~3.88), preeclampsia (3.05, 1.71~5.43) and SGA (1.90, 1.34~2.69), and had an earlier distribution of gestational weeks at delivery (P = 0.004) and a lower distribution of neonatal birth weights (P = 0.000), but the actual between-group differences were minuscule. The areas under ROC curves were 0.572 (P = 0.001), 0.579 (P = 0.015) and 0.565 (P = 0.000) for preterm birth, preeclampsia and SGA, respectively. Subdivisions for the disorders did not obviously improve the performances of MS-AFP.

Conclusions: Elevated first-trimester MS-AFP is associated with increased risk of preterm birth, preeclampsia and SGA. However, the predictive efficiencies were low and it is not a good predictor for these APOs.

Keywords: Alpha-fetoprotein; First-trimester; Preeclampsia; Preterm birth; Small for gestational age; Stillbirth.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Participants selection flowchart and the number of participants among subgroups of the study population
Fig. 2
Fig. 2
The ROC curves used to evaluate the predictive efficiencies of MS-AFP to preterm birth, stillbirth, preeclampsia and small for gestational age. The area under ROC curve was small (< 0.60) for the four APOs, and the significance was not obtained for stillbirth probably due to its lower incidence than that of the other three APOs. AUROC: the area under ROC curve
Fig. 3
Fig. 3
a The Kaplan-Meier curve used to record the gestational age at delivery for all participants. Women with MS-AFP ≥ 2.5 MoM had an earlier overall distribution of gestational weeks at delivery (Log-Rank test P = 0.004), but the overall difference was minuscule. b A boxplot showing the birth weights of all neonates. Women with MS-AFP ≥ 2.5 MoM had a lower overall distribution of neonatal birth weights (Median test P = 0.000), but the actual difference was minuscule: the medians of the two groups were 3200 and 3050 g respectively

Similar articles

Cited by

References

    1. Lawn JE, Blencowe H, Waiswa P, et al. Stillbirths: rates, risk factors, and acceleration towards 2030. Lancet. 2016;387:587–603. doi: 10.1016/S0140-6736(15)00837-5. - DOI - PubMed
    1. Lawn JE, Blencowe H, Oza S, et al. Every newborn: progress, priorities, and potential beyond survival. Lancet. 2014;384:189–205. doi: 10.1016/S0140-6736(14)60496-7. - DOI - PubMed
    1. Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–622. doi: 10.1056/NEJMoa1704559. - DOI - PubMed
    1. ACOG Committee Opinion No. 743 summary: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132:254–6. - PubMed
    1. Wilson RD. Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects. J Obstet Gynaecol Can. 2014;36:927–939. doi: 10.1016/S1701-2163(15)30444-8. - DOI - PubMed

Substances

LinkOut - more resources